Ranier's Compounding Laboratory PRO/PA/PH/AT 18mcg/1.8mg/ recall — FDA D-1092-2018
Lack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.
Complete FDA and NHTSA recall records dated in 2018, organized for browsing by month, category and recalling company.
Select a month to review the recall records reported during that period.
Records are ordered by the best available source date.
Lack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Lack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.
Presence of Foreign Substance: Product complaint was received of metal contaminant observed in one tablet.
Lack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.
Lack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.
Lack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.
Microbial Contamination of a Non-Sterile Product
Lack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.
Lack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Lack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.
Lack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.
Subpotent drug: The product active ingredient level not matching the exact levels indicated on the packaging label.
Lack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Lack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.
Lack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.
Lack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.
Lack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.
Volvo Car USA LLC (Volvo) is recalling certain 2019 Volvo XC40 vehicles. The brake pedals may not have been correctly riveted, allowing the pedal to move out of position, possibly reducing…
Revision rate identified as higher than other proximal radial head replacement devices based on literature review. Product may not perform at expected level post-surgery.
Revision rate identified as higher than other proximal radial head replacement devices based on literature review. Product may not perform at expected level post-surgery.
Mislabel of product 373726 Lot 6001700 with 374891 Lot 6001701 on individual packages within the correctly labeled shelf carton.
This archive groups records by their reported or recall date. It does not imply that every recall was initiated, announced and resolved during the same calendar year. Open the individual record for the exact dates and source details supplied by FDA or NHTSA.